Fig. 1From: PIVKA-II serves as a potential biomarker that complements AFP for the diagnosis of hepatocellular carcinomaExpression levels of serum PIVKA-II in patients with HCC, benign liver diseases (BLD) and healthy controls (HC)Back to article page